Preoperative Hemogram Parameters and BRAF Molecular Test Detected by Bethesda 3 Cytology.
Launched by SAGLIK BILIMLERI UNIVERSITESI · Aug 1, 2024
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how certain blood tests and a specific genetic test (BRAF testing) can help predict whether a thyroid nodule (a lump in the thyroid gland) is cancerous in patients whose cytology results are classified as Bethesda III. Bethesda III means that the cells from the nodule are somewhat unusual but not clearly cancerous. The researchers believe that looking at blood test results before surgery can provide useful information about the likelihood of cancer. They also think that the BRAF test, which checks for a specific gene change, can be a strong indicator of malignancy.
To be eligible for this trial, participants need to be between 18 and 75 years old and have been diagnosed with a Bethesda III thyroid nodule through a needle biopsy. They also need to be planning to have surgery to remove the nodule. If you join the study, you will have your blood tested to see if the results might indicate cancer, and you will also undergo BRAF testing. The trial is currently recruiting participants, and both men and women can take part. This study aims to improve how doctors determine the risk of cancer in patients with thyroid nodules, which could lead to better treatment decisions.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Patients between the ages of 18 -75
- • 2. Patients who were diagnosed with Bethesda III as a result of preoperative FNAC and decided to undergo thyroidectomy
- Exclusion Criteria:
- • 1. Patients over 18 years old and under 75 years old
- • 2. Patients with malignancy detected in another focus with preoperative Bethesda III FNAC
- • 3. Detection of malignancy in another focus other than the nodule with Bethesda III cytological result after thyroidectomy
- • 4. Failure to obtain preoperative hemogram results Patients who do not agree to participate in scientific studies for BRAF testing
About Saglik Bilimleri Universitesi
Saglik Bilimleri Universitesi, or the University of Health Sciences, is a leading academic institution dedicated to advancing healthcare through innovative research and clinical trials. With a strong emphasis on interdisciplinary collaboration, the university focuses on translating scientific discoveries into practical applications that enhance patient care and public health outcomes. Its commitment to rigorous ethical standards and comprehensive training equips researchers and healthcare professionals to contribute effectively to the global medical community. Through its clinical trial initiatives, Saglik Bilimleri Universitesi aims to address pressing health challenges and foster the development of new therapeutic strategies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Istanbul, , Turkey
Patients applied
Trial Officials
Ugur Kesici, Assoc.Prof.
Principal Investigator
Prof. Dr. Cemil Tascıoglu City Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported